|Original language||English (US)|
|Number of pages||3|
|Journal||Clinical Microbiology and Infection|
|State||Published - Dec 2019|
Bibliographical noteFunding Information:
Outside the current work, P.I.T. reports personal fees as a consultant and membership on the scientific advisory board for MediBeacon Inc.; he also holds equity in the company. P.I.T. and S.B.F. report personal fees as consultants for Takeda Pharmaceuticals, and P.I.T. reports consulting fees for the Bill & Melinda Gates Foundation on infant infections. S.B.F. reports non-financial support from Luminex Corporation, BioM?rieux and Copan Diagnostics to support research activities. In addition, PIT has a patent 20190142976 pending to MediBeacon Inc., and is an unpaid consultant to Immunova relating to development of a therapeutic agent for Shiga toxin-producing E. coli. S.B.F. is supported by the Alberta Children's Hospital Foundation Professorship in Child Health and Wellness.